Fig. 6From: Monitoring therapeutic efficacy of sunitinib using [18F]FDG and [18F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinomaLung metastasis incidence according to the primary tumour growth duration in control and treated groups. The percentage of lungs bearing metastasis is plotted against the delay between tumour implantation and resection. At 30 days, no lung metastasis is present in treated (n = 4) and control (n = 3) groups (set A). At 39 days, metastases are detected in half the lungs in both the 14 day-sunitinib treated group (n = 4) and the corresponding control group (n = 4) (set B)Back to article page